Abstract：
Erectile dysfunction (ED) is a common condition that negatively affects men\'s quality of life. It can have various causes, including psychological, vascular, and neurologic factors. Existing treatments for ED mainly focus on symptom relief rather than addressing the underlying cause. Stem cells (SCs) have shown potential as a therapeutic approach for ED due to their anti-inflammatory properties.
This systematic review aims to assess the current status of trials and determine the potential impact of SCs on male sexual health.
A comprehensive search strategy was employed to gather relevant articles from 6 electronic databases. The search included articles published until March 2023. The reference lists of articles were manually reviewed to identify additional studies of relevance. The eligibility criteria for inclusion in the analysis focused on clinical trials involving humans that evaluated the safety and efficacy of SC therapy for ED. Exclusion criteria encompassed case reports, case series, abstracts, reviews, and editorials, as well as studies involving animals or SC derivatives. Data extraction was performed via a standardized form with a focus on erectile outcomes.
A total of 2847 articles were initially identified; 18 were included in the final analysis. These studies involved 373 patients with ED and various underlying medical conditions. Multiple types of SC were utilized in the treatment of ED: mesenchymal SCs, placental matrix-derived mesenchymal SCs, mesenchymal SC-derived exosomes, adipose-derived SCs, bone marrow-derived mononuclear SCs, and umbilical cord blood SCs.
SC therapy shows promise as an innovative and safe treatment for organic ED. However, the lack of standardized techniques and controlled groups in many studies hampers the ability to evaluate and compare trials.
This systematic review aims to assess the current status of trials and determine the potential impact of SCs on male sexual health.
A comprehensive search strategy was employed to gather relevant articles from 6 electronic databases. The search included articles published until March 2023. The reference lists of articles were manually reviewed to identify additional studies of relevance. The eligibility criteria for inclusion in the analysis focused on clinical trials involving humans that evaluated the safety and efficacy of SC therapy for ED. Exclusion criteria encompassed case reports, case series, abstracts, reviews, and editorials, as well as studies involving animals or SC derivatives. Data extraction was performed via a standardized form with a focus on erectile outcomes.
A total of 2847 articles were initially identified; 18 were included in the final analysis. These studies involved 373 patients with ED and various underlying medical conditions. Multiple types of SC were utilized in the treatment of ED: mesenchymal SCs, placental matrix-derived mesenchymal SCs, mesenchymal SC-derived exosomes, adipose-derived SCs, bone marrow-derived mononuclear SCs, and umbilical cord blood SCs.
SC therapy shows promise as an innovative and safe treatment for organic ED. However, the lack of standardized techniques and controlled groups in many studies hampers the ability to evaluate and compare trials.
摘要：
背景：勃起功能障碍（ED）是一种常见的疾病，会对男性的生活质量产生负面影响。它可以有各种各样的原因，包括心理,血管,和神经因素。现有的ED治疗主要集中在症状缓解，而不是解决根本原因。干细胞(SC)由于其抗炎特性而显示出作为ED的治疗方法的潜力。
目的：本系统综述旨在评估试验的现状，并确定SC对男性性健康的潜在影响。
方法：采用综合检索策略，从6个电子数据库中收集相关文章。搜索包括直到2023年3月发布的文章。文章的参考列表进行了手动审查，以确定其他相关研究。纳入分析的资格标准集中于涉及人类的临床试验，这些临床试验评估了SC治疗ED的安全性和有效性。排除标准包括病例报告，案例系列,摘要,reviews,和社论，以及涉及动物或SC衍生物的研究。数据提取是通过标准化形式进行的，重点是勃起结果。
结果：最初确定了总共2847篇文章；最终分析中包括18篇。这些研究涉及373名患有ED和各种潜在医疗状况的患者。多种类型的SC用于治疗ED：间充质干细胞，胎盘基质间充质干细胞,间充质SC来源的外泌体，脂肪来源的SCs，骨髓来源的单核干细胞，和脐带血SCs。
结论：SC治疗有望成为有机ED的创新和安全治疗方法。然而,许多研究中缺乏标准化技术和对照组,这阻碍了对试验进行评估和比较的能力.
目的：本系统综述旨在评估试验的现状，并确定SC对男性性健康的潜在影响。
方法：采用综合检索策略，从6个电子数据库中收集相关文章。搜索包括直到2023年3月发布的文章。文章的参考列表进行了手动审查，以确定其他相关研究。纳入分析的资格标准集中于涉及人类的临床试验，这些临床试验评估了SC治疗ED的安全性和有效性。排除标准包括病例报告，案例系列,摘要,reviews,和社论，以及涉及动物或SC衍生物的研究。数据提取是通过标准化形式进行的，重点是勃起结果。
结果：最初确定了总共2847篇文章；最终分析中包括18篇。这些研究涉及373名患有ED和各种潜在医疗状况的患者。多种类型的SC用于治疗ED：间充质干细胞，胎盘基质间充质干细胞,间充质SC来源的外泌体，脂肪来源的SCs，骨髓来源的单核干细胞，和脐带血SCs。
结论：SC治疗有望成为有机ED的创新和安全治疗方法。然而,许多研究中缺乏标准化技术和对照组,这阻碍了对试验进行评估和比较的能力.
